Skip to content

Suhuang antitussive capsule in the treatment of bronchial asthma--a multi-center, randomized, double-blind, placebo-controlled clinical study

Suhuang antitussive capsule in the treatment of bronchial asthma--a multi-center, randomized, double-blind, placebo-controlled clinical study

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200005511
Enrollment
Unknown
Registered
2022-01-08
Start date
2022-01-10
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchial Asthma

Interventions

Experimental Group:Suhuang antitussive capsules
Placebo Control Group:Suhuang antitussive capsule simulators

Sponsors

Shanghai General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) Outpatients with chronic persistent of asthma who meet the typical asthma diagnostic criteria in the 2020 edition of the "Guidelines for the Prevention and Treatment of Bronchial Asthma"; (2) The severity is graded as mild or moderate, and the ACT score is =19 points; (3) Age from 18 to 60 years old; (4) Sign the informed consent form. Those who meet all the above criteria at the same time can be included in the study.

Exclusion criteria

Exclusion criteria: (1) Combined use of compound methoxyphenamine capsules, codeine tablets, codeine oral solution, compound pseudoephedrine hydrochloride oral solution, tabellae dextpomethorphani hydrobromiditablets, compound licorice tablets, Jizhi syrup, Shedan Chuanbei loquat ointment, Xianzhuli Oral Liquid, Qutanling Oral Liquid, Qutan Zhike capsules, Fei Li Ke Mixture, Xuanfei Zhisou Mixture and other medicines containing anti-cough ingredients, or Maxing Zhike Tablets, Gejie Dingchuan Pills and other Chinese traditional medicines containing ephedra ingredients within 2 weeks; (2) Patients with a history of arrhythmia, coronary atherosclerotic heart disease, hypertension or hyperthyroidism, and poor control; (3) Patients with severe heart, liver, kidney, brain, mental, or neurological diseases; (4) Allergic to drugs known in this study; (5) Pregnant or lactating women or those planning pregnancy; (6) Those who have participated in or are participating in other clinical trials within 28 days; (7) Those who are deemed unsuitable to participate in this trial by the researcher. Those who meet any of the above criterion cannot be included in this study.

Design outcomes

Primary

MeasureTime frame
ACT score;

Secondary

MeasureTime frame
Lung function;AQLQ score;Exploratory index;Safety index;LCQ score;Clinical symptom score;

Countries

China

Contacts

Public ContactZhang Min
maggie_zhangmin@163.com+86 13482345145

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026